Welcome to Adagio MedicalClinical Ideas, Academic Research, Technical Excellence, Entrepreneurial Spirit
A LEADING INNOVATOR IN TREATMENT OF CARDIAC ARRHYTHMIAS
Adagio Medical, an operating subsidiary of Adagio Medical Holdings, Inc. (NASDAQ:ADGM), is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (UTLC) technology. UTLC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vClas™ catheter, which is CE Marked and is currently under evaluation in the FULCRUM-VT U.S. IDE Pivotal Study.
OUR MISSION
The Adagio Medical, Inc. mission is to be a leading innovator in the treatment of cardiac arrhythmias, committed to improving patient outcomes by developing catheter ablation technologies of uncompromising durability, versatility and safety.
MANAGEMENT TEAM
Todd Usen
Chief Executive Officer
Deborah Kaster
Chief Financial Officer and Chief Business Officer
Nabil Jubran
Chief Compliance Officer
Alex Babkin
Chief Technical Officer
Ilya Grigorov
Vice President of Global Marketing and Product Management
Doug Kurschinski
Vice President of Clinical Affairs
Maryline Cullen
Corporate Controller
BOARD OF DIRECTORS
Orly Mishan
Chairperson
Todd Usen
James L. Cox
Timothy P. Moran
Sandra Gardiner
Keyvan Mirsaeedi-Farahani